Business of Cannabis
Last month, Germany’s Federal Joint Committee (G-BA) proposed significant changes to the medical cannabis prescription process, opening the door for medical cannabis to be prescribed via statutory health insurance (gesetzliche Krankenversicherung or GKV)
This would enable around 70% of practicing German physicians to prescribe medical cannabis without prior approval from health insurance companies, which would be reimbursed for patients.
While logic dictates these changes would lead to a spike in reimbursed prescriptions across the country, some industry insiders have suggested that the threat of ‘recourse’, in which doctors can still be held financially liable, is likely to continue to see prescribing practicians be extra cautious.
Read the report
